Preliminary brief— based on press release only. Full analysis including management tone and Q&A will be added when the transcript is available.

AFL · Q4 2025 Earnings

Aflac

Reported February 4, 2026

30-second summary

30-second take: Aflac closed 2025 with Q4 adjusted EPS of $1.57 on $4.87B revenue (-9.9% YoY, driven by lower net investment gains (~$500M swing YoY)) and an 11.7% adjusted ROE, but the substantive news is in 2026 guidance: Japan underlying earned premiums are now explicitly guided to decline 1-2%, and the Japan pre-tax margin range steps down to 33-36% from the 35-38% guided last quarter for FY2025 — 200 bps of structural compression at both ends of the range that management did not flag as transitory. The Q3 "inflection validated and quantified" thesis is now a Q3 thesis only; Q4 reframes the inflection as a "reasonable future" event with 2026 still net-negative on premium.

Headline numbers

EPS

Q4 FY2025

$1.57

Revenue

Q4 FY2025

$4.87B

-9.9% YoY

Key financials

Q4 FY2025

Metric	Q4 FY2025	YoY	Q3 FY2025	QoQ
Revenue	$4.87B	-9.9%	$4.74B	+2.7%
EPS	$1.57	—	$2.49	-36.9%

Guidance

Company provided full-year FY2026 operational guidance across Japan and U.S. segments with Japan premium growth expected to decline 1-2% and U.S. premium growth guided to lower end of 3-6% range; prior-year FY2025 guidance metrics were not reaffirmed as comparables.

Guidance is issued for the full year only, refreshed each quarter. Prior and new below are the same FY updated this quarter.

New guidance

Metric	Period	Guide	YoY
Japan benefit ratio	FY 2026	60% to 63%	—
Japan expense ratio	FY 2026	20% to 23%	—
Japan pre-tax profit margin	FY 2026	33% to 36%	—
Japan underlying earned premiums	FY 2026	decline 1% to 2%	—
U.S. benefit ratio	FY 2026	48% to 52%	—
U.S. expense ratio	FY 2026	36% to 39%	—
U.S. net-earned premium growth	FY 2026	lower end of the 3 to 6% range	—
U.S. pre-tax profit margin	FY 2026	17% to 20%	—

Reaffirmed unchanged this quarter: Japan benefit ratio (60% to 63%)

Segment performance

Q4 FY2025

Segment	Q4 FY2025	YoY
Aflac Japan	$0.712B	-4.7%
Aflac U.S.	$0.3B	-9.1%

Capital & returns

Q4 FY2025

Segment	Q4 FY2025
Adjusted Return on Equity (ROE)	11.7%
Adjusted Book Value Per Share (Diluted)	$54.06
Total Debt to Adjusted Capitalization ex-AOCI	21.4%
Adjusted Debt to Total Capitalization	24.7%

Other KPIs

Q4 FY2025

Segment	Q4 FY2025
Aflac U.S. Premium Persistency (12-mo rolling)	79.2%
Aflac U.S. Combined Ratio	82.6%
Aflac Japan Gross Premiums In Force	¥1,133.7 billion
Aflac U.S. Annualized Premiums In Force	$6.694 billion

Management tone

Q1 stabilization → Q2 inflection candidate → Q3 inflection validated and quantified → Q4 inflection deferred and margins reset lower

The Japan inflection thesis has been quietly pushed out by at least a year. Three quarters ago Yoshizumi committed "2025 sales will exceed 2024"; two quarters ago management quantified a 35-38% Japan pre-tax margin and 58-60% benefit ratio; this quarter Max said: "once that turns positive is eventually when we are going to have net earned premium growth in Japan. So we see that within a reasonable future, but even going into 2026, we still expect that lapses will be greater than total sales." The sales momentum thesis is intact; the translation-to-premium thesis is now indefinite. Pairing this with explicit 1-2% premium decline guidance for 2026 makes it the first time in four quarters management has guided premium down rather than toward stabilization.

Reserve remeasurement tailwinds have been recategorized from transitory to embedded. Last quarter Max disclosed the 130bps net-premium-ratio reduction as a tailwind to forward benefit ratios. This quarter the FY2026 Japan benefit ratio guide is higher, not lower (60-63% vs. 58-60% for FY2025). The 130bps benefit is now in the run-rate but is being offset by other mix and assumption changes that management did not unpack on the call. The net read: the favorable remeasurement was a one-time level shift, not a trend, and the underlying ratio is drifting up.

US legacy decline is now explicitly multi-year rather than cyclical. Virgil's "our traditional business has been flat to negative for the past few years, including last year. So when you have that anchor of a core business, you don't see the tremendous explosive growth that you are seeing, that we are seeing, though, on the group side" is the cleanest acknowledgment of structural US headwind this management has offered. The 2026 net-earned premium growth guide at "the lower end of 3 to 6%" — i.e., closer to 3% — is the quantitative reflection.

M&A posture has hardened from "patient" to effectively "not interested." Q2 framed elevated cash as a flat-curve stance; Q3 delivered a $1B buyback while keeping optionality; Q4 closes the door on inorganic: "we are operating in a relatively narrow niche, both in the United States and in Japan, and to sort of find operational and strategic targets within those niches is relatively difficult to find." Combined with ESR at 253% and adjusted debt/cap at 24.7%, the capital story has shifted to buyback-and-dividend by default, not by choice.

Recurring themes management leaned on this quarter:

Japan sales momentum offset by structural in-force runoff; premium growth inflection delayedNew product launches (Morito, On Shin Pallet, Sumitas) driving lapse/reissue activity and reserve releasesUS group benefits and direct-to-consumer channels scaling; traditional voluntary benefits persistently flatBenefit ratio expansion in US due to endorsement increases on pandemic-low-utilization products and business mix shiftCapital flexibility maintained but deployed tactically; ESR 253% with regulatory headroomAI deployment focused on claims automation and enrollment efficiency, not disintermediation of agents

Risks management surfaced:

Japan interest rate sensitivity on in-force savings block; potential for elevated surrenders if yen yields remain elevatedCommercial real estate and middle-market loan credit losses (charge-offs $22M in Q4; valuation allowances recorded)K-shaped economy and macroeconomic uncertainty affecting consumer behavior and agent recruitmentUS voluntary benefits traditional block structural decline continuing; reliance on group/new channels for offsetFX headwinds on Japan earnings translation (leverage ratio 21.4% impacted by yen/dollar movements)

Answers to last quarter's watch list

Japan benefit ratio landing within 58-60% — Management did not provide a clean FY2025 final benefit ratio readout for Japan in the disclosed materials; what is observable is that FY2026 is now guided to 60-63%, above the 58-60% FY2025 range. Either FY2025 landed at the high end of 58-60% and the guide reflects ongoing drift, or the 58-60% range was missed — either reading is unfavorable to the segment-margin credibility built in Q3. Status: Resolved negatively

US "buy-the-bills" second line to profitability — Not addressed in the prepared remarks or extracted commentary; the company didn't disclose. Status: Not resolved

Japan medical product launch (late December 2025) — Dan Amos confirmed the late-December launch of the new medical product (On Shin Pallet) and noted "positive reception" since introduction. Status: Confirmed; continue monitoring traction

US bundled-product traction in 2026 broker selling season — Virgil's explicit "flat to negative for the past few years" acknowledgment for traditional voluntary, combined with the FY2026 NEP guide at the lower end of 3-6%, says the bundling pivot is not yet visible in the planning assumptions. Status: Continue monitoring

Persistency in Japan post-Tsumitas repricing — Japan FY2025 gross premiums of ¥1,133.7B are consistent with continued runoff; management acknowledged some hedging language around demand and lapsation but stated they "have not experienced that yet." US persistency 79.2% is healthy. Status: Continue monitoring

Japan pre-tax margin trajectory toward upper half of 35-38% — Guide moved down to 33-36% for FY2026, not up within 35-38%. The mid-to-high-30s sustainable margin thesis from Q3 does not survive the Q4 reset. Status: Resolved negatively

What to watch into next quarter

Japan underlying earned premiums vs. -1% to -2% guide: any print worse than -2% would extend the "reasonable future" inflection language into 2027 and force a second reset.

Japan benefit ratio Q1 print relative to 60-63%: the high end of the new range is 300bps worse than the high end of the prior range. Watch whether Q1 lands closer to 60% or to 63%.

US benefit ratio normalization: the 48-52% range for 2026 assumes the endorsement-driven expansion seen in Q4 is durable. Q1 will show whether 82.6% Q4 US combined ratio was a one-quarter mix issue or a 2026 baseline.

Buyback pace given M&A explicitly deprioritized: with ESR 253%, adjusted debt/cap 24.7%, and no acquisitions in scope, capital return should accelerate. Watch Q1 buyback vs. Q3's $1B record.

Variable NII and credit charge migration: $22M of Q4 charge-offs and CRE/middle-market valuation allowances flagged but quantified small — Q1 will show whether this is contained or widening.

Any restatement of Japan FY2025 final benefit ratio: a published number above 60% would confirm the FY2025 guidance was missed and explain the FY2026 reset.

Sources

Aflac Q4 2025 Financial Supplement, SEC filing: https://www.sec.gov/Archives/edgar/data/4977/000162828026005458/afl123125-fabdocument.htm
Aflac Q4 2025 earnings call commentary (Dan Amos, Max Brodén, Virgil Miller, Yoshizumi, Koide).

Get the next brief, free.

We publish analyst-grade earnings briefs the same day or morning after every call — headline numbers, segment KPIs, Q&A highlights, and tone analysis. Free during beta.

This is not investment advice.